Xlife Sciences AG Logo

Xlife Sciences AG

XLS | SW

Overview

Corporate Details

ISIN(s):
CH0461929603 (+1 more)
LEI:
984500AH590BE88BB517
Country:
Switzerland
Address:
Talacker 35, 8001 Zürich
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Xlife Sciences AG is a Swiss company that operates as a life sciences incubator and accelerator. It focuses on the value development and commercialization of promising, early-stage research projects sourced from universities and other research institutions. The company's mission is to bridge the gap between academic research and healthcare markets by advancing solutions for high unmet medical needs. Xlife Sciences concentrates its investments and development efforts across four key pillars: technology platforms, biotechnologies/therapies, medical technology (healthtech), and the application of artificial intelligence in digital health.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Xlife Sciences AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-17 07:00
Registration Form
Xlife Sciences AGs Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward …
English 12.6 KB
2025-07-17 02:00
M&A Activity
Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward…
English 15.5 KB
2025-07-17 02:00
Registration Form
Portfoliounternehmen der Xlife Sciences AG, VERAXA Biotech AG, erreicht wichtig…
German 16.4 KB
2025-06-24 18:00
Post-Annual General Meeting Information
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
English 6.1 KB
2025-06-24 02:00
Post-Annual General Meeting Information
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
English 8.2 KB
2025-06-24 02:00
Post-Annual General Meeting Information
Xlife Sciences AG: Erfolgreiche Generalversammlung und Wachstumsaussichten in 2…
German 8.5 KB
2025-06-16 16:00
Regulatory News Service
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and Onc…
English 9.8 KB
2025-06-16 02:00
Regulatory News Service
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and Onc…
English 12.3 KB
2025-06-16 02:00
M&A Activity
Strategische Zusammenarbeit zwischen Xlife Sciences AG, Huraypositive Corp. und…
German 13.4 KB
2025-06-13 17:42
M&A Activity
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Acc…
English 9.0 KB
2025-06-13 02:00
M&A Activity
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Acc…
English 11.4 KB
2025-06-13 02:00
Regulatory News Service
Strategische Allianz zwischen Xlife Sciences AG, JIPYONG LLC und JIPYONG IP sol…
German 12.9 KB
2025-05-07 07:00
Environmental & Social Information
Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company F…
English 9.9 KB
2025-05-05 07:00
Report Publication Announcement
Xlife Sciences AG confirms sustainable value development and strategic scaling …
English 5.4 KB
2025-04-25 07:00
Annual Report
Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technologi…
English 7.2 KB

Automate Your Workflow. Get a real-time feed of all Xlife Sciences AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Xlife Sciences AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-15 N/A Executive member Buy None 6,000.00 CHF
2022-06-15 N/A Executive member Buy None 3,000.00 CHF
2022-06-14 N/A Executive member Buy None 15,500.00 CHF
2022-06-10 N/A Executive member Buy None 6,728.90 CHF
2022-06-07 N/A Executive member Buy None 34,800.00 CHF
2022-06-03 N/A Executive member Buy None 3,540.00 CHF
2022-05-24 N/A Executive member Buy None 3,400.00 CHF
2022-05-17 N/A Executive member Buy None 10,794.20 CHF
2022-05-13 N/A Executive member Buy None 3,690.00 CHF
2022-05-10 N/A Executive member Buy None 1,935.00 CHF

Peer Companies

Company Country Ticker View
United States of America N/A
RYVU Therapeutics S.A. Logo
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
Poland RVU
Saniona Logo
Biopharma developing medicines for epilepsy and neurological disorders using ion channel research.
Denmark SANION
SAREUM HOLDINGS PLC Logo
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
United Kingdom SAR
SCANCELL HOLDINGS PLC Logo
Developing therapeutic vaccines and antibodies for cancer and infectious diseases.
United Kingdom SCLP
Scandion Oncology A/S Logo
A liquidated biotech that developed oral drugs to overcome cancer treatment resistance.
Denmark SCOL
SCIENCE GROUP PLC Logo
International science & tech consultancy providing advisory, R&D, and product development.
United Kingdom SAG
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services for life sciences.
Poland SLV
Sensorion Logo
Clinical-stage biotech developing novel therapies for hearing loss, vertigo, and tinnitus.
France ALSEN
Simris Group AB Logo
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden SIMRIS